This session focuses on practical clinical challenges in the management of patients receiving radiopharmaceutical therapies (RPT).  Expert speakers discuss a broad range of common challenges related to radiation safety, renal and hematologic dysfunction, response assessment and decisions about di

While most oncologists are familiar with the development, execution and reporting of interventional clinical trials that improve patient outcomes, there are unique challenges that must be considered when evaluating radioactive drugs.

This session will review the latest science in the field of radiopharmaceutical therapy.

This session covers the experiences of the radiopharmaceutical therapy programs at three institutions.

This session explores critical operational, clinical and administrative considerations for maturing and optimizing established radiopharmaceutical and theranostics programs.

This session reviews the latest science in the field of radiopharmaceutical therapy.

Increasing access and addressing unmet needs are critical to the continued growth and adoption of radiopharmaceutical therapy. This session summarizes the current barriers to access and discuss solutions to increase physician and patient access to these important therapies.

Session describes the logistics behind radiopharmaceutical therapy (RPT) administration, starting with drug receipt, preparation, infusion, and finishing with patient release.  The session highlights the role of the qualified medical physicist (QMP) in ensuring safety, quality, and regulatory com

This session explores two essential components of a successful RPT program: authorized user credentialing process and structured training for medical physicists. It includes a step-by-step overview of the regulatory pathway for obtaining AU status, including required training and documentation.

This session offers a comprehensive and candid review of the evolution, current impact, and future direction of radiotheranostics, with a particular focus on PSMA targeted imaging and therapy in prostate cancer.